Drug class
Deoxycytidine nucleoside; pyrimidine nucleoside replacement component of KYGEVVI
Mechanism of action
Supplies deoxycytidine for mitochondrial DNA nucleotide pools. In thymidine kinase 2 deficiency, the combination of deoxycytidine and deoxythymidine is intended to support mitochondrial DNA maintenance and synthesis; the individual nucleosides are administered as a fixed combination, not as separately indicated monotherapies.
General use cases
- Component of the fixed combination doxecitine/doxribtimine (KYGEVVI) for treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with symptom onset on or before 12 years of age; not a stand-alone approved indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
